Epigenetic markers of prostate cancer in plasma circulating DNA

NCUIR > college of Health Sciences and Technology > Department of Biomedical Sciences and Engineering > journal & Dissertation > Item 987654321/102742

Please use this identifier to cite or link to this item: https://ir.lib.ncu.edu.tw/handle/987654321/102742

Title:	Epigenetic markers of prostate cancer in plasma circulating DNA
Authors:	王孫崇;Cortese, Rene;Kwan, Andrew;Lalonde, Emilie;Bryzgunova, Olga;Bondar, Anna;Wu, Ying;Gordevicius, Juozas;Park, Mina;Oh, Gabriel;Kaminsky, Zachary;Tverkuviene, Justina;Laurinavicius, Arvydas;Jankevicius, Feliksas;Sendorek, Dorota H.S.;Haider, Syed;Wang, Sun-Chong;Jarmalaite, Sonata;Laktionov, Pavel;Boutros, Paul C.;Petronis, Arturas
Contributors:	生醫理工學院生醫科學與工程學系
Keywords:	Aged;Benign;Biomarkers, Tumor - blood;Biomarkers, Tumor - genetics;Case-Control Studies;Centromere;Chromosomes, Human, Pair 10;Cytosine - chemistry;DNA Methylation;DNA, Circular - blood;Epigenesis, Genetic;Gene Expression Regulation, Neoplastic;Humans;Male;Microarray Analysis - methods;Middle Aged;Prostatic Hyperplasia - genetics;Prostatic Neoplasms - genetics;Repetitive Sequences, Nucleic Acid;Sensitivity and Specificity
Date:	2012-08-01
Issue Date:	2026-04-23 11:15:58 (UTC+8)
Publisher:	Oxford University Press;England
Abstract:	摘要： Epigenetic differences are a common feature of many diseases, including cancer, and disease-associated changes have even been detected in bodily fluids. DNA modification studies in circulating DNA (cirDNA) may lead to the development of specific non-invasive biomarkers. To test this hypothesis, we investigated cirDNA modifications in prostate cancer patients with locally confined disease (n = 19), in patients with benign prostate hyperplasias (n = 20) and in men without any known prostate disease (n = 20). This initial discovery screen identified 39 disease-associated changes in cirDNA modification, and seven of these were validated using the sodium bisulfite-based mapping of modified cytosines in both the discovery cohort and an independent 38-patient validation cohort. In particular, we showed that the DNA modification of regions adjacent to the gene encoding ring finger protein 219 distinguished prostate cancer from benign hyperplasias with good sensitivity (61%) and specificity (71%). We also showed that repetitive sequences detected in this study were meaningful, as they indicated a highly statistically significant loss of DNA at the pericentromeric region of chromosome 10 in prostate cancer patients (p = 1.8 × 10(-6)). Based on these strong univariate results, we applied machine-learning techniques to develop a multi-locus biomarker that correctly distinguished prostate cancer samples from unaffected controls with 72% accuracy. Lastly, we used systems biology techniques to integrate our data with publicly available DNA modification and transcriptomic data from primary prostate tumors, thereby prioritizing genes for further studies. These data suggest that cirDNA epigenomics are promising source for non-invasive biomarkers. 其他題名： Hum Mol Genet 出版者： England 出版日期： 2012-08-15 出處： Human molecular genetics, 2012-08, Vol.21 (16), p.3619-3631 識別號： ISSN: 0964-6906 識別號： ISSN: 1460-2083 識別號： EISSN: 1460-2083 識別號： DOI: 10.1093/hmg/dds192 識別號： PMID: 22619380
Appears in Collections:	[Department of Biomedical Sciences and Engineering ] journal & Dissertation

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	25	View/Open

社群 sharing

Loading...